Dr. Weisel on Interim Analysis With Isatuximab Plus KRd in High-Risk Myeloma

Katja Weisel, MD, of the University Hospital Hamburg, discusses the interim analysis of the phase 2 GMMG-Concept trial with isatuximab-irfc (Sarclisa) in combination with carfilzomib (Kyprolis), lenalidomide, and dexamethasone (KRd) in high-risk patients with newly diagnosed multiple myeloma.

Data from an interim analysis of the GMMG-Concept trial were presented during the 2020 European Hematology Association Congress. The analysis focused on the first 50 patients who were included in the trial and their response to induction treatment with isatuximab plus KRd, says Weisel. Of those included in the interim analysis, 46 patients were transplant eligible and 4 patients were transplant ineligible. Results showed that all 50 patients were evaluable for response and all patients responded to the treatment; an overall response rate of 100% was reported. Additionally, 90% of patients had a very good partial response or better, adds Weisel. Forty-six percent of patients achieved a complete remission with the combination.

Patients were also analyzed for minimal residual disease (MRD). At this early time point, 33 patients were analyzed for MRD; 20 of these patients were MRD negative, 11 were positive, and 2 were not evaluable, according to Weisel. Investigators are hopeful that the patients with MRD positivity will become negative during the first treatment course. These results were encouraging to see in such a high-risk myeloma patient population, concludes Weisel.